1uzu: Difference between revisions
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
The binding of indirubin-5-sulphonate (E226), a potential anti-tumour, agent and a potent inhibitor (IC(50) = 35 nm) of cyclin-dependent kinase 2, (CDK2) and glycogen phosphorylase (GP) has been studied by kinetic and, crystallographic methods. Kinetic analysis revealed that E226 is a, moderate inhibitor of GPb (K(i) = 13.8 +/- 0.2 micro m) and GPa (K(i) =, 57.8 +/- 7.1 micro m) and acts synergistically with glucose. To explore, the molecular basis of E226 binding we have determined the crystal, structure of the GPb/E226 complex at 2.3 A resolution. Structure analysis, shows clearly that E226 binds at the purine inhibitor site, where caffeine, and flavopiridol also bind [Oikonomakos, N.G., Schnier, J.B., Zographos, S.E., Skamnaki, V.T., Tsitsanou, K.E. & Johnson, L.N. (2000) J. Biol., ... | The binding of indirubin-5-sulphonate (E226), a potential anti-tumour, agent and a potent inhibitor (IC(50) = 35 nm) of cyclin-dependent kinase 2, (CDK2) and glycogen phosphorylase (GP) has been studied by kinetic and, crystallographic methods. Kinetic analysis revealed that E226 is a, moderate inhibitor of GPb (K(i) = 13.8 +/- 0.2 micro m) and GPa (K(i) =, 57.8 +/- 7.1 micro m) and acts synergistically with glucose. To explore, the molecular basis of E226 binding we have determined the crystal, structure of the GPb/E226 complex at 2.3 A resolution. Structure analysis, shows clearly that E226 binds at the purine inhibitor site, where caffeine, and flavopiridol also bind [Oikonomakos, N.G., Schnier, J.B., Zographos, S.E., Skamnaki, V.T., Tsitsanou, K.E. & Johnson, L.N. (2000) J. Biol., Chem.275, 34566-34573], by intercalating between the two aromatic rings of, Phe285 and Tyr613. The mode of binding of E226 to GPb is similar, but not, identical, to that of caffeine and flavopiridol. Comparative structural, analyses of the GPb-E226, GPb-caffeine and GPb-flavopiridol complex, structures reveal the structural basis of the differences in the potencies, of the three inhibitors and indicate binding residues in the inhibitor, site that can be exploited to obtain more potent inhibitors. Structural, comparison of the GPb-E226 complex structure with the active pCDK2-cyclin, A-E226 complex structure clearly shows the different binding modes of the, ligand to GPb and CDK2; the more extensive interactions of E226 with the, active site of CDK2 may explain its higher affinity towards the latter, enzyme. | ||
==About this Structure== | ==About this Structure== | ||
1UZU is a | 1UZU is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Oryctolagus_cuniculus Oryctolagus cuniculus] with PLP and INR as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Phosphorylase Phosphorylase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.4.1.1 2.4.1.1] Structure known Active Site: PLP. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1UZU OCA]. | ||
==Reference== | ==Reference== | ||
Line 31: | Line 31: | ||
[[Category: transferase]] | [[Category: transferase]] | ||
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 5 13:11:24 2007'' |